Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwig, Heinz, Delforge, Michel, Facon, Thierry, Einsele, Hermann, Gay, Francesca, Moreau, Philippe, Avet-Loiseau, Hervé, Boccadoro, Mario, Hajek, Roman, Mohty, Mohamad, Cavo, Michele, Dimopoulos, Meletios A, San-Miguel, Jesús F, Terpos, Evangelos, Zweegman, Sonja, Garderet, Laurent, Mateos, María-Victoria, Cook, Gordon, Leleu, Xavier, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin, Weisel, Katja, van de Donk, Niels W. C. J., Waage, Anders, Beksac, Meral, Mellqvist, Ulf H., Engelhardt, Monika, Caers, Jo, Driessen, Christoph, Bladé, Joan, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035147/
https://www.ncbi.nlm.nih.gov/pubmed/29720735
http://dx.doi.org/10.1038/s41375-018-0040-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035147/
https://www.ncbi.nlm.nih.gov/pubmed/29720735
http://dx.doi.org/10.1038/s41375-018-0040-1

Ejemplares similares